The FDA approved Lembaz, the first drug shown to help infantile-onset Niemann-Pick C patients live longer
The FDA approved Lembaz, a spinal injection every two weeks. Among 36 treated patients, median survival was 8.5 years versus 4.9 in matched controls. It carries a boxed warning for hearing loss.

Read the original
The reporting lives at U.S. Food and Drug Administration. Our summary is checked against it, and we link it on every story.
The FDA approved Lembaz (adrabetadex) on November 17, 2026, the first treatment shown to help people with infantile-onset Niemann-Pick disease type C live longer. It is approved to reduce the risk of death in adults and children who weigh at least 7 kilograms, about 15 pounds, and whose neurological symptoms began before age 6. A trained clinician gives it as an injection into the spinal canal every two weeks.
The agency compared 36 patients treated with Lembaz, across three studies and an expanded-access program, with a matched external control group. Treated patients had a 55 percent lower risk of death. Median survival was 8.5 years in the treated group and 4.9 years in the control group. The FDA said that difference held whether or not patients were also taking miglustat. Lembaz carries a boxed warning for hearing impairment, including permanent hearing loss. Hearing should be checked before treatment and regularly after, and the dose may change based on those tests. Two earlier drugs for Niemann-Pick type C were already approved, and the FDA said neither had been shown to reduce the risk of death. These figures describe the 36 treated patients and their matched controls. They are not a promise for every person with the disease.
Health & Tech in MarylandSilver Spring, MarylandMedical researchPublic healthGood news on November 17
More good news
Other stories in the same neighborhood of kindness.
Health & TechFDA approves Roche's oral pill giredestrant for advanced breast cancer
The FDA approved giredestrant with everolimus for a specific advanced breast cancer. In a 207-patient trial it cut the risk of progression or death by 62%.
Verified · Reuters
Health & TechThe FDA approved a pre-surgery bladder cancer combo
The FDA approved durvalumab, sold as Imfinzi, plus enfortumab vedotin before bladder removal, then durvalumab afterward, for muscle-invasive bladder cancer in patients who cannot take cisplatin or who decline it. In the 695-patient VOLGA trial the combo cut the risk of an event by about half. It is not a cure.
Verified · U.S. Food and Drug Administration
Health & TechThe FDA approved the first drug for a rare kidney disease
The FDA approved Gazyva, obinutuzumab, for adults with primary membranous nephropathy at risk of getting worse, to induce remission of protein in the urine. In a 142-person trial, 36 percent reached complete remission at week 104, compared with 6 percent on tacrolimus. It is not a cure.
Verified · U.S. Food and Drug Administration